TherOx® is a privately held medical device company focused on improving treatment of acute myocardial infarction (AMI), of the firm's SuperSaturated Oxygen (SSO2) Therapy system upon receipt of Food and Drug Administration (FDA) premarket approval (PMA). In business from the early 1990's and having raised serious VC when that was no easy task,. Expected to do well, the firm was among those falling vicitim to the Great Recession when its IPO had eventually to be withdrawn. The firm nonetheless has continued to find financial suport for its work. TherOxs IC-HOT (Evaluation of Intracoronary Hyperoxemic Oxygen Therapy) study results confirmed the safety and effectiveness of SSO2 Therapy in treatment of anterior AMI patients who have undergone successful percutaneous coronary intervention (PCI) with stenting within six hours of experiencing AMI symptoms. These confirmatory results build on the successful outcome of the AMIHOT II controlled, randomized pivotal trial that studied the first-generation SSO2 Therapy system. SSO2 Therapy circulates the patients own blood via the existing arterial access site used for the stenting procedure meaning that no new access site is required. SSO2 Therapy is intended to reduce infarct size by boosting oxygen delivery to the heart muscle immediately after the coronary artery has been opened by PCI. The TherOx SSO2 Therapy system delivers a one-time, 60-minute infusion of superoxygenated blood to the coronary arteries after standard-of-care treatment for heart attack has been completed. SSO2 Therapy is intended to provide interventional cardiologists with the first treatment option beyond PCI to salvage heart muscle in heart attack patients. Although PCI is the standard of care in treating AMI, for many patients it doesnt sufficiently reduce infarct size to achieve maximum clinical benefit. Adjunctive to PCI, SSO2 Therapy is intended to salvage heart muscle and reduce infarct size. In June 2019 it was announced that TherOx had been acquired by Zoll Corporation Medical Corporation, an Asahi Kasei Group Company that manufactures medical devices and related software solutions. TherOx is focused on improving treatment of acute myocardial infarction (AMI) and markets systems to deliver SuperSaturated Oxygen (SSO2) Therapy.
